Skip to content

CytomX Therapeutics CTMX Ratios & Valuation

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
Profitability
Operating margin-181.9%-153pp-29.4%-49.8pp20.5%-10.1pp30.6%+6.2pp24.4%+6.3pp
Net margin-166.4%-144pp-22.8%-47.4pp24.7%-9.3pp34%+5.8pp28.2%+5.1pp
Returns
Return on equity-34.3%
Efficiency
Asset turnover0.2×-0.4×0.6×-0.2×0.8×-0.1×0.8×-0.2×+0.2×
Liquidity
Current ratio10.4×+7.3×3.1×-0.5×3.6×-0.6×4.2×+2.5×1.7×+0.5×
Leverage
Debt-to-equity0.0×0.0×0.1×0.0×0.1×-0.3×0.3×
Per Share
Book value per share$1.80+151%$0.72+10.3%$0.65-29.9%$0.93+223%$0.29+5,422%
Valuation
Market capitalization$711.89M+94.8%$721.79M+37.2%$526.07M+56.0%$337.14M+562%$50.93M-36.8%
Price / sales20×+17.6×9.5×+4.8×4.6×+2.2×2.4×+2.0×0.3×-0.2×
Price / book2.2×-12.4×7.3×+2.4×4.9×+2.1×2.8×+0.8×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do CytomX Therapeutics's ratios come from?
Every ratio is computed from CytomX Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.